December 23, 2023

Karuna’s top asset is KarXT, an experimental antipsychotic with a promising novel mechanism. It’s currently being reviewed by the USFDA for treatment of schizophrenia in adults

Retail analysts expect overall sales will grow at a slower pace than last year, and there is concern over how shoppers are paying for things

Americans have also been slow to get other vaccinations. Only about 18% have gotten an updated Covid-19 shot that became available in September